Molecure S.A.

WSE:MOC Rapporto sulle azioni

Cap. di mercato: zł166.7m

Molecure Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Marcin Szumowski

Amministratore delegato

zł473.2k

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEOno data
Proprietà del CEO0.7%
Durata media del management3.8yrs
Durata media del Consiglio di amministrazione2.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Aug 20
Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Apr 20
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Dec 01
We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Jul 07
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Mar 10
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Aug 16
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Nov 04
OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24
Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02
Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

AMMINISTRATORE DELEGATO

Marcin Szumowski

no data

Mandato

zł473,205

Compensazione

Dr. Marcin Jan Szumowski, Ph D., is employed at Life Science Innovations Fund. He has been Chief Executive Officer and President of the Management Board at Molecure S.A. (formerly known as OncoArendi Thera...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Marcin Szumowski
Co-Founderno datazł473.21k0.70%
PLN 1.2m
Slawomir Broniarek
CFO & Member of the Management Boardno datazł421.09k0.20%
PLN 341.6k
Zbigniew Zaslona
Chief Scientific Officer & Member of Management Board2.8yrszł473.21k0.11%
PLN 187.0k
Agnieszka Rajczuk-Szczepanska
Member of Management Board & HR Director4.8yrszł348.41k0.034%
PLN 57.4k
Adam Golebiowski
Co-Founder & VP of Research Chemistry12.8yrszł500.00k3.01%
PLN 5.0m
Jacek Olczak
Co-Founder & Head of Medicinal Chemistryno dataNessun datoNessun dato
Piotr Iwanowski
Chief Medical Officer & Member of Management Boardless than a yearNessun datoNessun dato
Magdalena Tyszkiewicz
Head of CMC4.8yrsNessun datoNessun dato
Marta Borkowska
Director of the Management Board Office2.8yrsNessun datoNessun dato

3.8yrs

Durata media

Gestione esperta: Il team dirigenziale di MOC è considerato esperto (durata media dell'incarico 3.8 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Luke O'Neill
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Bart Lambrecht
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Tomasz Piec
Vice Chairman of the Supervisory Board4.8yrszł133.62kNessun dato
Douglas Hay
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Paul Van Der Horst
Independent Chairman of the Supervisory Board2.8yrszł132.99k0.059%
PLN 99.0k
Nancy Van Osselaer
Independent Member of the Supervisory Board2.8yrszł124.22kNessun dato
Agnieszka Motyl
Member of the Supervisory Board1.3yrszł44.45kNessun dato
Pawel Trawkowski
Independent Member of the Supervisory Board2.4yrszł124.22kNessun dato

2.8yrs

Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di MOC non è considerato esperto (durata media del mandato 2.8 anni), il che suggerisce un nuovo consiglio.